Moderated by Dean Martha Minow of the Harvard Law School, this panel focused on the impact of the Supreme Court's 2013 decision in the Myriad case that naturally occurring DNA cannot be patented. Will this be a boon for patients and a burden for biotech companies? Will sufficient incentive remain for innovation? Will there be any practical change at all?

Panelists:
Eric Lander, Director of the Broad Institute of MIT and Harvard, Professor of Biology at MIT, and Professor of Systems Biology at Harvard Medical School

I. Glenn Cohen, Professor of Law, Harvard Law School; Faculty Co-Director of the Petrie-Flom Center

Benjamin N. Roin, Hieken Assistant Professor in Patent Law, Harvard Law School; Faculty Co-Director of the Petrie-Flom Center

Claire LaPorte, Partner, Foley Hoag LLP

Tania Simoncelli, former Science Advisor to the ACLU

Co-sponsored by the Broad Institute of MIT and Harvard.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…